By Colin Kellaher

 

Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said Libtayo showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma in an open-label phase 2 study.

The companies said the study involves patients who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy, for whom there are currently no approved treatments.

Regeneron and Sanofi said they plan to make regulatory filings this year.

Basal cell carcinoma, a skin cancer, is the most common cancer worldwide.

Sanofi and Regeneron last week said they had stopped a pivotal phase 3 trial of Libtayo in advanced non-small cell lung cancer early due to a highly significant improvement in positive overall survival.

Regeneron, of Tarrytown, N.Y., and France's Sanofi are jointly developing and commercializing Libtayo under a global collaboration agreement.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

May 05, 2020 10:42 ET (14:42 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Sanofi Charts.